Close

New report estimates nearly 18 million cancer survivors in the US by 2022

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Buyout of SpringWorks Brings Back Merck KGaA in the M&A Game

Merck KGaA’s long-standing courtship of SpringWorks Therapeutics has finally...

Roche Looks to Expand its Drug Production in the US

Roche is planning to expand its drug production in...

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

The number of Americans with a history of cancer, currently estimated to be 13.7 million, will grow to almost 18 million by 2022, according to a first-ever report by the American Cancer Society in collaboration with the National Cancer Institute (NCI). The report, Cancer Treatment and Survivorship Facts and Figures, and accompanying journal article published in CA: A Cancer Journal for Clinicians, used data from the NCI-funded Surveillance, Epidemiology, and End Results (SEER) Program to generate brand new estimates of cancer survivor prevalence in the U.S. The reports find that even though cancer incidence rates are decreasing, the number of cancer survivors is growing due to the aging and growth of the population, as well as improving cancer survival rates.

The growing number of cancer survivors in the U.S. makes it increasingly important to understand the unique medical and psychosocial needs of survivors and raise awareness of resources that can assist patients, caregivers, and health care providers in navigating the various phases of cancer survivorship. The reports were created to highlight the challenges and opportunities to serve these survivors.

The three most common cancers among males living with a history of cancer in 2012 are prostate cancer (43%), colorectal cancer (9%), and melanoma (7%). Among women in 2012 with a history of cancer, the three most common cancers are breast (41%), uterine (8%), and colorectal (8%) cancer. In 2022, those proportions are expected to be largely unchanged.

Other selected findings:

Nearly one-half (45%) of cancer survivors are aged 70 years or older, while only 5% are aged younger than 40 years

The median age of patients at the time of cancer diagnosis is 66.

There are 58,510 survivors of childhood cancer living in the United States, and an additional 12,060 children will be diagnosed in 2012.

The majority of cancer survivors (64%) were diagnosed 5 or more years ago; 15% were diagnosed 20 or more years ago.

In addition to prevalence estimates, the reports also include information on treatment, survival, and common concerns of survivors for eleven selected cancers, as well as sections on the effects of cancer and its treatment, palliative care, long term survivorship, the benefits of healthy behaviors, and resources for cancer survivors from the American Cancer Society and other organizations.

“With this effort, we review the critical issues related to cancer treatment and survivorship,” said Elizabeth R. Ward, Ph.D., national vice president of Intramural Research and senior author of the report. “Many survivors, even among those who are cancer free, must cope with the long-term effects of treatment, as well as psychological concerns such as fear of recurrence. As more people survive cancer, it is vital that health care providers are aware of the special needs of cancer patients and caregivers.”

Latest stories

Related stories

Buyout of SpringWorks Brings Back Merck KGaA in the M&A Game

Merck KGaA’s long-standing courtship of SpringWorks Therapeutics has finally...

Roche Looks to Expand its Drug Production in the US

Roche is planning to expand its drug production in...

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back